Here’s the dividend forecast for GSK shares through to 2026!
City brokers expect dividends on GSK shares will keep marching higher. Is the FTSE 100 share a top passive income stock to ...
Endpoints News4h
GSK fol­lows Pfiz­er in meningo­coc­cal vac­cine race with new FDA nod
GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.
US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
Fierce Pharma6h
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
ROSEN, A LEADING NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Rosen Law Firm PAWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...
Citadel takes $384.5 million short position in GSK - FT
Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
The Financial Express20h
Q3FY25: GSK pharma’s profit surges 4X to Rs 229 crore; Revenue up 18 percent
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...
GSK plc (NYSE:GSK) Shares Sold by Kingsview Wealth Management LLC
Kingsview Wealth Management LLC lowered its holdings in GSK plc (NYSE:GSK – Free Report) by 11.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...